Offer - Urjas Oil for just ₹ 1 X
Combimist LD Respules is an allopathic medicine The correct dosage of Combimist LD Respules depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Combimist LD Respules is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Combimist LD Respules safe for pregnant women?
Combimist LD Respules can have harmful effects in pregnant women. If you experience any discomfort after using Combimist LD Respules, then discontinue the use and take your doctor's advice.
Is the use of Combimist LD Respules safe during breastfeeding?
If you are breastfeeding, you may experience some harmful effects of Combimist LD Respules. In case you experience any of these, discontinue its use until you consult your doctor.
What is the effect of Combimist LD Respules on the Kidneys?
Combimist LD Respules rarely harms the kidneys.
What is the effect of Combimist LD Respules on the Liver?
Combimist LD Respules is rarely harmful for the liver.
What is the effect of Combimist LD Respules on the Heart?
You may experience side effects on your heart after taking Combimist LD Respules. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
Combimist LD Respules should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Combimist LD Respules unless your doctor advises you to do so -
Is this Combimist LD Respules habit forming or addictive?
Combimist LD Respules is not addictive in nature.
Interaction between Food and Combimist LD Respules
Information is not available on the interaction of any foods with Combimist LD Respules, due to a lack of research on this.
Interaction between Alcohol and Combimist LD Respules
Due to lack of research, there is no information about the side effects of taking Combimist LD Respules with alcohol.
No, Combimist LD Respules does not cause weight gain. It has not been reported by the patients who are taking this drug. If you are experiencing rapid weight gain after taking this drug, then it might be due to some other reason and you are advised to discuss it with your doctor.
Yes, Combimist LD Respules is a bronchodilator. It is a short-acting bronchodilator which dilates the bronchi and bronchioles.
Yes, Combimist LD Respules can be used to provide relief from whizzing in the treatment of bronchitis. It opens the airway which allows easy breathing.
Combimist LD Respules is a bronchodilator which causes widening of bronchial smooth muscles present in the lungs which get tightened causing a constriction. Due to the constriction, the air cannot pass in and out of your lungs, and the relaxation of these bronchial muscles results in dilation of airways. This helps the patients breathe more easily which provides relief to the patient from the symptoms such as wheezing, and chest tightness.
Yes, Combimist LD Respules is safe to use, if taken in prescribed amount and duration as advised by the doctor. However, certain side effects have been associated with this drug such as palpitations, headache, and dizziness. If you experience any discomfort after taking this medicine then inform your doctor immediately and follow his/her instructions.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 705
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 116
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Atrovent® HFA (ipratropium bromide HFA)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ipravent® (ipratropium bromide)